FindTrial
Sign In

Effect of metagenome next-generation sequencing on anti-infective therapy in patients with febrile neutropenia: a prospective multicenter randomized controlled clinical study

Effect of metagenome next-generation sequencing on anti-infective therapy in patients with febrile neutropenia: a prospective multicenter randomized controlled clinical studyudy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100042992
Enrollment
Unknown
Registered
2021-02-03
Start date
2021-03-01
Completion date
Unknown
Last updated
2021-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

febrile neutropenia

Interventions

Experimental group:mNGS to guide the treatment
Control group:none

Sponsors

The Affiliated Drum Tower Hospital of Nanjing University Medical School
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years, no gender limitation; 2. Patients with malignant hematologic diseases and febrile neutropenia with high risk factors according to the guideline; 3. No antibiotics were used (except prophylactic antibiotics) in the week before enrollment; 4. Signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Lack of treatment compliance; 2. Be diagnosed as hemophagocytic lymphohistiocytosis; 3. Be considered inappropriate by researchers.

Design outcomes

Primary

MeasureTime frame
Antifebrile time;—

Secondary

MeasureTime frame
Intensity of antibiotic use;Antibiotic cost;Duration of antibiotic use;—

Countries

China

Contacts

Public ContactOuyang Jian

The Affiliated Drum Tower Hospital of Nanjing University Medical School

oy626@sina.com+86 13770518202

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 7, 2026